Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia

被引:1
|
作者
Yunivita, Vycke [1 ,2 ]
Gafar, Fajri [1 ,3 ,4 ]
Santoso, Prayudi [5 ,6 ]
Chaidir, Lidya [2 ,7 ]
Soeroto, Arto Y. [5 ,6 ]
Meirina, Triana N. [8 ]
Te Brake, Lindsey [9 ]
Menzies, Dick [3 ,4 ]
Aarnoutse, Rob E. [9 ]
Ruslami, Rovina [1 ,2 ,4 ]
机构
[1] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Div Pharmacol & Therapy, Bandung, Indonesia
[2] Univ Padjadjaran, Res Ctr Care & Control Infect Dis, TB Working Grp, Bandung, Indonesia
[3] Res Inst McGill Univ Hlth Ctr, Ctr Outcomes Res & Evaluat, Resp Epidemiol & Clin Res Unit, 5252 Blvd Maisonneuve Ouest,Off 3D 21, Montreal, PQ H4A 3S5, Canada
[4] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada
[5] Univ Padjadjaran, Fac Med, Dept Internal Med, Div Respirol & Crit Care, Bandung, Indonesia
[6] Hasan Sadikin Gen Hosp, Bandung, Indonesia
[7] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Div Microbiol, Bandung, Indonesia
[8] Univ Padjadjaran, Fac Med, Pharmacokinet Lab, Bandung, Indonesia
[9] Radboud Univ Nijmegen Med Ctr, Radboud Inst Med Innovat, Dept Pharm, Nijmegen, Netherlands
关键词
BACTERICIDAL ACTIVITY; CULTURE CONVERSION; TB PATIENTS; DRUGS; PHENOTYPE; GENOTYPE;
D O I
10.1093/jac/dkae057
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background :Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify predictors of exposures, and explore exposure-response relationships in RR/MDR-TB patients. Methods: We performed an observational pharmacokinetic study, with exploratory pharmacokinetic/pharmacodynamic analyses, in Indonesian adults aged 18-65 years treated for pulmonary RR/MDR-TB with standardized regimens containing high-dose isoniazid (10-15 mg/kg/day) for 9-11 months. Intensive pharmacokinetic sampling was performed after >= 2 weeks of treatment. Total plasma drug exposure (AUC(0-24)) and peak concentration (Cmax) were assessed using non-compartmental analyses. AUC(0-24)/MIC ratio of 85 and C-max/MIC ratio of 17.5 were used as exposure targets. Multivariable linear and logistic regression analyses were used to identify predictors of drug exposures and responses, respectively. Results :We consecutively enrolled 40 patients (median age 37.5 years). The geometric mean isoniazid AUC(0-24 )and Cmax were 35.4 h center dot mg/L and 8.5 mg/L, respectively. Lower AUC0-24 and Cmax values were associated (P < 0.05) with non-slow acetylator phenotype, and lower Cmax values were associated with male sex. Of the 26 patients with MIC data, less than 25% achieved the proposed targets for isoniazid AUC(0-24)/MIC (n = 6/26) and C-max/MIC (n = 5/26). Lower isoniazid AUC0-24 values were associated with delayed sputum culture conversion (>2 months of treatment) [adjusted OR 0.18 (95% CI 0.04-0.89)]. Conclusions :Isoniazid exposures below targets were observed in most patients, and certain risk groups for low isoniazid exposures may require dose adjustment. The effect of low isoniazid exposures on delayed culture conversion deserves attention.
引用
收藏
页码:977 / 986
页数:10
相关论文
共 50 条
  • [21] HIGH-DOSE MEFLOQUINE IN THE TREATMENT OF MULTIDRUG-RESISTANT FALCIPARUM-MALARIA
    TERKUILE, FO
    NOSTEN, F
    THIEREN, M
    LUXEMBURGER, C
    EDSTEIN, MD
    CHONGSUPHAJAISIDDHI, T
    PHAIPUN, L
    WEBSTER, HK
    WHITE, NJ
    JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06): : 1393 - 1400
  • [22] A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis Results from a Randomized Clinical Trial
    Gausi, Kamunkhwala
    Ignatius, Elisa H.
    Sun, Xin
    Kim, Soyeon
    Moran, Laura
    Wiesner, Lubbe
    von Groote-Bidlingmaier, Florian
    Hafner, Richard
    Donahue, Kathleen
    Vanker, Naadira
    Rosenkranz, Susan L.
    Swindells, Susan
    Diacon, Andreas H.
    Nuermberger, Eric L.
    Dooley, Kelly E.
    Denti, Paolo
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 204 (11) : 1327 - 1335
  • [23] The efficacy and safety of high-dose isoniazid-containing therapy for multidrug-resistant tuberculosis: a systematic review and meta-analysis
    Zhou, Ming
    Liu, Ai-Mei
    Yang, Xiao-Bing
    Guan, Cui-Ping
    Zhang, Yan-An
    Wang, Mao-Shui
    Chen, Ya-Li
    FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [24] Emergence of a multidrug-resistant tuberculosis through inadequate treatment of isoniazid monoresistance
    Frueh, Jonas
    Strasen, Joern
    Held, Matthias
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (20) : 1222 - 1226
  • [25] Molecular Characterization of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Strains Isolated in Kazakhstan
    Kozhamkulov, Ulan
    Akhmetova, Ainur
    Rakhimova, Saule
    Belova, Elena
    Alenova, Arike
    Bismilda, Venera
    Chingissova, Lyailya
    Ismailov, Shahimurat
    Ramanculov, Erlan
    Momynaliev, Kuvat
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2011, 64 (03) : 253 - 255
  • [26] Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients
    Chirehwa, Maxwell T.
    Court, Richard
    de Kock, Mariana
    Wiesner, Lubbe
    de Vries, Nihal
    Harding, Joseph
    Gumbo, Tawanda
    Maartens, Gary
    Warren, Rob
    Denti, Paolo
    McIlleron, Helen
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (10)
  • [27] Treatment of Infection as a Core Strategy to Prevent Rifampicin-Resistant/Multidrug-Resistant Tuberculosis
    Reuter, Anja
    Furin, Jennifer
    PATHOGENS, 2023, 12 (05):
  • [28] Treatment of multidrug-resistant tuberculosis
    Colebunders, R
    Apers, L
    Shamputa, IC
    LANCET, 2004, 363 (9416): : 1240 - 1240
  • [29] Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis
    Huang, Chuan-Chin
    Becerra, Mercedes C.
    Calderon, Roger
    Contreras, Carmen
    Galea, Jerome
    Grandjean, Louis
    Lecca, Leonid
    Yataco, Rosa
    Zhang, Zibiao
    Murray, Megan
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 202 (08) : 1159 - 1168
  • [30] Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high-dose ciprofloxacin
    WongBeringer, A
    Beringer, P
    Lovett, MA
    CLINICAL INFECTIOUS DISEASES, 1997, 25 (04) : 936 - 937